• Gilead Sciences reached a public reimbursement agreement with the pan-Canadian Pharmaceutical Alliance for LYVDELZI (seladelpar), its primary biliary cholangitis treatment.
• The agreement clears the national pricing hurdle; individual public drug plans will determine formulary listings and reimbursement criteria.
• Some public drug plans could begin reimbursing eligible patients as early as 2027, with rollout timing varying by jurisdiction.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via CNW (Ref. ID: 202610270800CANADANWCANADAPR_C5594) on October 27, 2026, and is solely responsible for the information contained therein.